Literature DB >> 16034545

A novel canine model of spinal cord ischemia with reproducible neurologic outcomes.

Yuji Sugawara1, Hajime Kumagai, Taijiro Sueda.   

Abstract

PURPOSE: To develop a canine model of spinal cord ischemia (SCI) with highly reproducible neurologic outcomes.
METHODS: Spinal cord ischemia was induced by cross-clamping the proximal descending aorta. To produce substantial ischemia in the critical lumbar region, the proximal aortic blood pressure (PAP) was reduced to 80 mmHg by withdrawing blood into a reservoir connected to the left subclavian artery. We conducted an intraischemia spinal cord electrophysiologic study and a postischemia assessment of hindlimb motor function in six animals subjected to this procedure with an aortic occlusion time of 40 min, and in six animals subjected only to aortic occlusion for 60 min.
RESULTS: All the animals subjected to this procedure exhibited a significant decrease in motor-evoked spinal cord potentials to transcranial electric stimulation (MEPs) during the acute ischemic phase, and they were paraplegic 48 h after ischemia. In contrast, two of the animals not subjected to PAP reduction showed complete functional recovery with intact MEP findings.
CONCLUSION: This model is feasible for experimental SCI studies because it can reliably and easily reproduce substantial ischemia.

Entities:  

Mesh:

Year:  2005        PMID: 16034545     DOI: 10.1007/s00595-005-2994-7

Source DB:  PubMed          Journal:  Surg Today        ISSN: 0941-1291            Impact factor:   2.549


  10 in total

1.  The arterial supply of the spinal cord and its significance.

Authors:  D H WOOLLAM; J W MILLEN
Journal:  J Neurol Neurosurg Psychiatry       Date:  1955-05       Impact factor: 10.154

2.  Selective deep hypothermia of the spinal cord prevents paraplegia after aortic cross-clamping in the dog model.

Authors:  R Berguer; J Porto; B Fedoronko; L Dragovic
Journal:  J Vasc Surg       Date:  1992-01       Impact factor: 4.268

3.  Cyclosporin A reduces delayed motor neuron death after spinal cord ischemia in rabbits.

Authors:  Minato Sato; Takashi Horinouchi; Masahiro Sakurai; Noritaka Murakami; Shun Sato; Masato Kato
Journal:  Ann Thorac Surg       Date:  2003-04       Impact factor: 4.330

4.  Ischemic preconditioning protects against paraplegia after transient aortic occlusion in the rat.

Authors:  V S Abraham; J A Swain; A J Forgash; B L Williams; M M Musulin
Journal:  Ann Thorac Surg       Date:  2000-02       Impact factor: 4.330

5.  The effect of direct lidocaine injection into the clamped aortic segment on the spinal evoked potential: early diagnosis for spinal cord ischemia.

Authors:  H Nohara; M Okada; C Yamashita; K Ataka; N Yoshimura
Journal:  Ann Thorac Cardiovasc Surg       Date:  1999-02       Impact factor: 1.520

6.  The influence of severity of spinal cord ischemia in the etiology of delayed-onset paraplegia.

Authors:  W M Moore; L H Hollier
Journal:  Ann Surg       Date:  1991-05       Impact factor: 12.969

7.  Prevention of spinal cord ischemia by selective intercostal arterial infusion of prostaglandin E1.

Authors:  H Ohtake; H Urayama; S Katada; M Tamura; M Kawasuji; Y Watanabe
Journal:  J Vasc Surg       Date:  1998-08       Impact factor: 4.268

8.  Protecting the ischemic spinal cord during aortic clamping: the influence of selective hypothermia and spinal cord perfusion pressure.

Authors:  W Wisselink; M O Becker; J H Nguyen; S R Money; L H Hollier
Journal:  J Vasc Surg       Date:  1994-05       Impact factor: 4.268

9.  Relationship between evoked potentials and clinical status in spinal cord ischemia.

Authors:  Y Kai; J H Owen; B T Allen; M Dobras; C Davis
Journal:  Spine (Phila Pa 1976)       Date:  1994-05-15       Impact factor: 3.468

10.  An experimental study on spinal cord ischemia during cross-clamping of the thoracic aorta: the monitoring of spinal cord ischemia with motor evoked potential by transcranial stimulation of the cerebral cortex in dogs.

Authors:  S Shokoku; H Uchida; S Teramoto
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.